{"filings":[{"id":1195998,"accession_number":"0001493152-26-029599","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-06-22T20:35:33+00:00","items":["5.07"],"status":"ready","headline":"Aspire Biopharma stockholders approve three warrant-related proposals at special meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrant Issuance Proposal: 1,742,683 for, 107,523 against, 4,818 withheld, 0 non-votes.","Share Adjustment Proposal: 1,745,709 for, 103,550 against, 5,764 withheld, 0 non-votes.","Exercise Price Adjustment Proposal: 1,739,702 for, 110,483 against, 4,839 withheld, 0 non-votes.","All proposals related to warrants on common stock (ASBP) and warrants (ASBPW) under terms of Warrant Agreement dated March 17, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1029759,"accession_number":"0001493152-26-028518","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-06-12T21:15:29+00:00","items":["8.01"],"status":"ready","headline":"Aspire Biopharma adjourns shareholder meeting due to insufficient quorum, reschedules to June 16","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting adjourned on June 9, 2026, after failing to reach quorum.","Rescheduled to June 16, 2026, at 10:00 a.m. (EST).","Virtual meeting link remains www.colonialstock.com/AspireBiopharma2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1013676,"accession_number":"0001493152-26-028386","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-06-12T14:26:16+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma signs $30M cash deal for auto supplier DCS with >$200M revenue","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["DCS generated >$200M revenue, >$22M Adjusted EBITDA, >$17M net income in FY2025 (unaudited).","Purchase price $30M cash; no new equity financing expected; closing targeted Q3 2026.","DCS operates 11 global facilities, holds 310+ patents, serves 150+ vehicle platforms and blue-chip OEMs.","Existing DCS CEO Hans Vorstenbosch continues; leadership bolstered by Lakewood & Company with 200+ years experience.","Acquisition transforms Aspire into diversified high-revenue enterprise while advancing drug delivery technology."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442518,"accession_number":"0001493152-26-023069","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-05-14T20:05:32+00:00","items":["5.03","9.01"],"status":"ready","headline":"Aspire Biopharma files 1-for-30 reverse stock split","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed 1-for-30 reverse stock split of common stock on May 11, 2026.","Fractional shares rounded up; no fractional shares will be issued in the split.","Ticker symbol remains ASBP; new CUSIP number is 738920305.","Effective date set in the Certificate of Amendment filed with Delaware Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96181,"accession_number":"0001493152-26-018018","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspire Biopharma closes $21M private placement, secures $22.5M credit facility for DCS acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed second tranche of $10M (12,500 preferred shares); total gross proceeds $21M from private placement.","Commitment letter for up to $22.5M senior secured credit facility to fund proposed $30M cash acquisition of DCS.","DCS (automotive supplier) had $200M+ revenue and $20M+ adjusted EBITDA in FY2025 (unaudited).","Stockholders' equity now exceeds $2.5M Nasdaq minimum; no new equity anticipated to consummate DCS purchase."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96176,"accession_number":"0001493152-26-017145","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K/A","filed_at":"2026-04-17T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Aspire Biopharma closes second tranche of $21M preferred offering; funds Dura Driver acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed second tranche of Series A Convertible Preferred stock on April 15, 2026 for 12,500 shares and gross proceeds of ~$10M.","Combined with first tranche (13,750 shares, $11M), total offering raises $21M before fees.","Amended Certificate of Designation to increase authorized Series A shares from 25,000 to 30,000.","Net proceeds to fund cash portion of proposed Dura Driver Control Systems acquisition and for general corporate purposes.","RBW Capital Partners acting through Dawson James Securities acted as placement agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96180,"accession_number":"0001493152-26-017115","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["1.01","5.03","9.01"],"status":"ready","headline":"Aspire Biopharma closes $10M second tranche of Series A preferred offering; amends certificate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second closing issued 12,500 Series A Convertible Preferred Shares for gross proceeds of $10,000,000.","Combined with prior closing of 13,750 shares ($11M including $943,801 debt conversion), total 30,000 shares designated.","Company believes stockholders' equity now exceeds $2.5M minimum for continued Nasdaq listing.","Certificate of Amendment filed Apr 13, 2026 designating 30,000 Series A shares with $1,000 stated value each.","Conversion price set at 80% of lowest closing price over 5 days before conversion; floor price at 20% of Nasdaq Minimum Price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96179,"accession_number":"0001493152-26-017054","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aspire Biopharma shareholders approve reverse stock split and authorized share increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split ratio range 1:5 to 1:500 approved: 2,096,356 for, 582,185 against, 12,852 abstain.","Authorized common stock increase from 490M to 700M shares passed: 1,925,368 for, 524,501 against, 7,403 abstain.","Series A Preferred issuance for conversion shares and floor price approved: 1,466,141 for, 203,756 against, 8,652 abstain, 1,012,844 broker non-votes.","ELOC Agreement share issuance approved: 1,469,985 for, 203,926 against, 4,638 abstain, 1,012,844 broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96178,"accession_number":"0001493152-26-016979","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Aspire Biopharma signs LOI to acquire automotive supplier DCS for $30M; DCS had $200M+ revenue in FY2025","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchase price of $30M cash for 100% of DCS; DCS generated >$200M revenue and >$22M adjusted EBITDA in FY2025 (unaudited).","DCS is a tier-one auto supplier with 310 patents, 11 global facilities, serving 150+ vehicle platforms across major OEMs.","Management from Lakewood & Company (100+ years auto experience) to bolster DCS leadership; deal subject to due diligence and audit.","RBW Capital Partners is exclusive financial advisor; Dawson James Securities will provide brokerage services for the acquisition.","Aspire plans to become a diversified, high-revenue enterprise; no definitive agreement executed yet and no assurance of completion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96177,"accession_number":"0001493152-26-016683","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-04-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Aspire Biopharma signs LOI to acquire Driver Controls Systems unit for $30M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered non-binding LOI to acquire Driver Controls Systems business unit of Firefish Topco for $30M cash-free, debt-free.","Purchase price payable in cash at closing; no new equity raise anticipated.","Break-up fees of $3.5M applicable under certain circumstances; 30-day no-shop period.","Company plans to engage Lakewood & Company for management services post-closing.","Acquisition subject to definitive agreement; LOI non-binding except for exclusivity, confidentiality, and break-up fees."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109860,"accession_number":"0001493152-26-006343","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-02-12T23:59:59+00:00","items":["1.01","3.02","8.01","5.02","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma raises up to $21M via convertible preferred stock; board adds Balatsos","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial closing of 13,750 Series A Convertible Preferred Shares for $11M gross proceeds; up to $21M total available.","Preferred shares convertible into common at 80% of lowest 5-day VWAP prior to conversion, subject to 4.99% ownership cap.","Company expects to regain Nasdaq stockholders' equity compliance (min $2.5M) after the offering.","Donald G. Fell resigned from board; Philip Balatsos appointed to fill vacancy.","RBW Capital Partners acted as placement agent; proceeds to support operations and reduce legacy debt."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109859,"accession_number":"0001493152-26-005640","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-02-06T23:59:59+00:00","items":["5.03","1.01","9.01"],"status":"ready","headline":"Aspire Biopharma files Series A Convertible Preferred Stock with 80% discount conversion and price protection","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Designation for 25,000 shares of Series A Convertible Preferred Stock on Feb 2, 2026.","Conversion price at 80% of lowest closing price in 5 prior trading days; floor price at 20% of Nasdaq minimum price.","Beneficial ownership conversion cap at 4.99% (can increase to 9.99% with 61-day notice).","Holders get participation rights in 30% of future financings for 6 months; no voting rights.","Shares rank senior to common; price protection adjusts conversion price on lower-priced issuances."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109858,"accession_number":"0001493152-26-004543","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Aspire Biopharma raises $2M via 8% OID debentures with 790K incentive shares","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $2,173,913 principal of 8% OID debentures for $2,000,000; maturity sooner of 90 days or $8M financing event.","Debentures are non-convertible, bear no interest; 790,000 shares of common stock issued as incentive shares.","Proceeds to be used for debt repayment and working capital; offering exempt under Section 4(a)(2)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109857,"accession_number":"0001493152-26-002326","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Aspire Biopharma Board sets share limit for 2024 Stock Incentive Plan at 4,890,000 shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board confirmed share limit of 4,890,000 shares for the 2024 Stock Incentive Plan, which was approved by stockholders in Feb 2025.","Approved forms of Restricted Stock Unit and Stock Option award agreements under the Plan.","Plan allows grants of equity awards to employees, directors, and consultants to align with long-term stockholder interests."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109856,"accession_number":"0001493152-26-002057","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Aspire Biopharma director Surendra Ajjarapu resigns effective Jan 7, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Surendra Ajjarapu resigned as Director of Aspire Biopharma, effective January 7, 2026.","Resignation not due to any disagreement with the Company, Board, or management.","No replacement for the vacant director position has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109855,"accession_number":"0001493152-26-000518","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","2.03","9.01"],"status":"ready","headline":"Aspire Biopharma converts ~$1.75M debt from PowerUp sponsors into common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exchanged ~$1.75M debt for common stock at closing price less $0.01/share; holders can submit up to 4 exchange notices by Jan 31, 2026.","Each exchange notice limited to 30% of outstanding balance; shares are freely tradeable without restrictive legends.","Upon a financing over $3M, company may repay debt; holder can elect 25% of outstanding balance from proceeds.","Exchange exempt under Section 3(a)(9) of Securities Act; debt originated from 2024 subscription agreements with PowerUp sponsors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126397,"accession_number":"0001493152-25-022580","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-11-14T23:59:59+00:00","items":["1.01","1.02","2.03","3.02","9.01"],"status":"ready","headline":"Aspire Biopharma enters $100M ELOC with Arena, terminates prior ELOC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered into $100M equity line of credit (ELOC) with Arena Business Solutions, effective Nov 11, 2025.","Prior $100M ELOC with Arena dated Feb 13, 2025 mutually terminated on same day.","Company may sell shares at 96% of VWAP; maximum advance amount varies by time of notice (up to $20M).","Issued transaction fee shares and paid $40,000 in fees (cash and shares) to Arena.","ELOC term is 36 months; subject to ownership limitation of 9.99% and Nasdaq exchange cap until shareholder approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126396,"accession_number":"0001493152-25-020891","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Aspire Biopharma holders approve reverse split (1:5-1:40) and 19.99%+ note issuance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split proposal passed: 24,965,481 for, 5,988,513 against, 29,704 abstain.","Notes proposal under Nasdaq Rule 5635(d) passed: 19,852,827 for, 3,747,867 against, 7,374,427 broker non-votes.","Reverse split ratio range 1:5 to 1:40; board has discretion to implement within one year.","Notes issued under Aug 19, 2025 purchase agreements; conversion floor price is 20% of 5-day avg closing prior to closing.","Ticker ASBP (common) and ASBPW (warrants) listed on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126395,"accession_number":"0001493152-25-018512","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Nasdaq notifies Aspire Biopharma of delisting for MVLS and bid price non-compliance; company appeals","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["On Oct 15, 2025, Nasdaq Staff notified the Company of delisting due to failure to comply with the MVLS Rule ($50M minimum) and Bid Price Rule ($1.00 minimum).","The Company failed to regain compliance within the 180-day period that ended on October 13, 2025.","The Company requested a hearing before the Nasdaq Hearings Panel and paid a $20,000 fee, which stays the suspension pending the Panel's decision.","The Company will present a plan to regain compliance and may request an extension of up to 180 additional days.","There is no assurance that the Panel will grant continued listing or that compliance can be regained."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143154,"accession_number":"0001493152-25-015773","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["3.02","4.01"],"status":"ready","headline":"Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.","Appointed Turner Stone & Co. as new independent auditor for FY 2025, effective Sept 22, 2025.","No disagreements with Bush; material weaknesses in internal control over financial reporting were disclosed.","Received $1M second tranche funding under Securities Purchase Agreement for notes with aggregate principal $9.6875M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143153,"accession_number":"0001641172-25-025257","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-08-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspire Biopharma raises $7.75M via convertible notes with 20% OID, maturity Feb 2026","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Aggregate principal $9.6875M issued at $7.75M subscription price (20% OID) for three tranches.","Notes mature Feb 19, 2026; convertible at 80% of lowest closing price in prior 5 trading days.","Proceeds to pay off debt and for working capital; RBW Capital Partners received 8% commission.","Registration rights agreement requires resale registration statement filed by Sept 18, 2025.","Company may prepay at 20% premium; conversion capped at 4.99% (or 9.99%) beneficial ownership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143152,"accession_number":"0001641172-25-021595","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-07-30T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"CEO and two directors resign; interim CEO appointed; director cites irreconcilable differences","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Howe steps down as CEO and Director effective July 24, 2025; no disagreement with company.","Kraig Higginson, Chairman, appointed Interim CEO; company searching for permanent CEO.","Gary Stein resigns as independent Director and Audit Committee chair; Howard Doss succeeds him.","Barbara Sher resigns as director citing irreconcilable differences with company policies and direction.","No disagreements cited for Howe or Stein; Sher's resignation letter provided to company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161272,"accession_number":"0001641172-25-015653","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Aspire Biopharma moves principal executive office to Estero, Florida","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board changed principal executive office to 23150 Fashion Drive, Suite 232, Estero, FL 33928 effective June 17, 2025.","Former address was 194 Candelaro Drive, #233, Humacao, Puerto Rico 00791.","New office is the company's principal place of business and headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161271,"accession_number":"0001641172-25-014445","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-06-10T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma CEO Kraig Higginson Steps Down, Michael C. Howe Appointed as New CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Kraig Higginson resigned as CEO effective June 10, 2025, and will serve as Executive Chairman.","Board appointed Michael C. Howe, previously an independent board member, as CEO effective June 10, 2025.","Howe led MinuteClinic from 19 clinics to sale to CVS in 2006, delivering nearly sixfold return for investors.","Howe has 40+ years experience at Procter & Gamble, PepsiCo, Arby's (CEO), and early-stage healthcare companies.","Press release issued June 10, 2025, detailing leadership transition and Howe's background."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161270,"accession_number":"0001641172-25-007852","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-04-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Aspire Biopharma settles lender default claims, extends note maturities by 75 days","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lenders withdrew April 1 and April 9 default/acceleration notices; defaults deemed cured with no admission of fault.","Maturities extended: Dec 13 note to Aug 15, 2025; Sep/Oct 2024 notes to Sep 10, 2025.","Company to issue 625,000 shares to Blackstone and file S-1 registration by May 13, 2025.","Lock-ups removed for Cobra, Blackstone, Thor; new leak-out restrictions based on trading volume through Aug 20, 2025.","Lenders waived additional interest/penalties; company to pay up to $60,000 in deal costs added to principal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161269,"accession_number":"0001641172-25-005427","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Aspire Biopharma receives Nasdaq delisting notices for MVLS below $50M and bid price under $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received two letters on April 16, 2025: MVLS deficiency (below $50M for 30 consecutive days) and bid price deficiency (below $1.00).","Company has 180 days until October 13, 2025 to regain compliance with MVLS; must achieve at least $50M for 10 consecutive business days.","Bid Price Rule allows 180-day compliance period; failure may lead to delisting or transfer to Nasdaq Capital Market.","Company is evaluating potential responses but has not decided on actions; no assurance of regaining compliance.","Tickers affected: ASBP (common stock) and ASBPW (warrants), both on Nasdaq Global Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179424,"accession_number":"0001493152-25-007898","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["1.01","2.01","9.01","4.01","2.03","3.02","3.03","5.03","5.01","5.02","5.05","5.06","7.01"],"status":"ready","headline":"Aspire Biopharma closes SPAC merger with PowerUp; issues $3.75M convertible debentures","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Business combination closed Feb 17, 2025: Aspire Biopharma becomes wholly owned sub of Aspire Biopharma Holdings (ASBP). Outstanding: 46M shares, 14.4M warrants.","Issued $3.75M principal of 20% OID convertible debentures for $3M net; conversion at 92.5% of 5-day VWAP (floor $4.00). Also issued 2.1M commitment shares.","New CEO Kraig Higginson (salary $180k) and CFO Ernest Scheidemann ($90k). Board: Howe, Stein, Sher, Kimball, Ajjarapu, Fell.","Blackstone Capital receives 1.795M commitment shares as amendment for working capital loans; lock-up and non-competition agreements executed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179423,"accession_number":"0001493152-25-007732","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["1.01","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Aspire Biopharma closes SPAC merger, lists on Nasdaq; enters $100M equity line","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Completed business combination with PowerUp Acquisition Corp.; began trading on Nasdaq Feb 20 under ASBP/ASBPW.","Proceeds from transaction total approx $3.8M including trust account and PIPE financing.","Entered $100M ELOC agreement with Arena; 96% of VWAP with $4.00 floor; 1,893,473 commitment shares issued.","Lead product is fast-absorbing aspirin for cardiology emergencies; plans FDA fast track 505(b)(2) NDA.","Management led by CEO Kraig Higginson; board of seven directors including Michael Howe, Gary E. Stein."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179425,"accession_number":"0001493152-25-005641","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["5.07","8.01","9.01"],"status":"ready","headline":"PowerUp shareholders approve merger with Aspire Biopharma; redemptions of ~$5.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All proposals approved at Feb 4 meeting, including business combination, domestication, and charter changes.","507,631 shares redeemed for $5.8M ($11.43/share), leaving ~$5.8M removed from trust.","Closing expected before Feb 17, 2025; combined company to trade as ASBP (common) and ASBPW (warrants) on Nasdaq.","Seven directors elected to staggered board, including Kraig Higginson, Michael Howe, Gary Stein, others.","Adjournment proposal not needed due to sufficient votes for all proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196129,"accession_number":"0001493152-24-052097","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-12-26T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"PowerUp secures up to $500K loan from Blackstone (Aspire insider) at 20% OID to fund merger","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Blackstone may loan up to $500,000 principal; $184,543.80 drawn as of Dec. 18, 2024.","Loan has 20% original issue discount, 10% annual interest, and 10% exit fee.","Maturity is earlier of June 1, 2025 or $5M gross proceeds from a debt/equity offering.","At Business Combination close, Sponsor transfers 3 PWUP Class A shares per dollar loaned to Blackstone.","Commitment Shares registered under Registration Rights Agreement included in the deal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196128,"accession_number":"0001493152-24-040725","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-10-10T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp extends Aspire merger disclosure schedule delivery to Oct 11, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second Amendment Agreement moves Disclosure Schedule Delivery Date to October 11, 2024.","Allows additional time for due diligence and compilation of disclosure schedules.","No changes to merger consideration, equity incentive pool, or other key terms.","Amendment is in connection with the previously announced business combination with Aspire Biopharma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196127,"accession_number":"0001493152-24-039574","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. agrees to pay sponsor $1M fee upon closing of Aspire Biopharma deal","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsor SRIRAMA Associates to receive $1M modified promissory note fee upon successful closing of Aspire Biopharma business combination.","Original $2M fee from terminated Visiox BCA replaced by this $1M fee.","Fee included as Purchaser Expenses in the Aspire BCA dated August 26, 2024.","Agreement dated October 2, 2024 between SPAC and Sponsor."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212410,"accession_number":"0001493152-24-035298","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. amends Aspire Biopharma merger; consideration set at $350M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger consideration adjusted to $350M less cash shortfall and debt, reflecting anticipated ownership percentages.","Equity incentive plan pool set at greater of 10% of post-closing shares or 5M shares, with annual evergreen provision.","Disclosure schedule delivery date extended to September 18, 2024, with 7-day review and cure period.","Amendment signed September 5, 2024, provides additional time for due diligence and disclosure schedules.","Deal remains subject to shareholder approvals and Nasdaq listing standards."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212409,"accession_number":"0001493152-24-034714","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-09-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PowerUp Acquisition announces definitive merger with Aspire Biopharma at $316M pre-money valuation","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Pre-money equity value of Aspire approximately $316 million.","Combined company to be named 'Aspire Biopharma Holdings, Inc.' and list on Nasdaq under 'ASPH'.","Existing Aspire shareholders expected to retain majority ownership after closing.","Expected closing end of Q4 2024 or beginning of Q1 2025; subject to regulatory and stockholder approvals.","Aspire's lead product Instaprin (soluble aspirin) targeting 505(b)(2) NDA with FDA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212408,"accession_number":"0001493152-24-034646","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-08-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. enters into definitive merger agreement with Aspire Biopharma valued at $316.8M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Consideration to Aspire stockholders: shares of New Aspire Common Stock valued at $316.8M less indebtedness and cash shortfall.","Post-closing board: 7 directors (2 from PowerUp, 5 from Aspire); CEO and CFO to be Aspire's current officers.","Closing conditions include shareholder approvals, SEC effectiveness of Form S-4, Nasdaq listing, and no material adverse effects.","No termination fees; outside date of August 17, 2025 to consummate the transaction.","PowerUp will domesticate from Cayman Islands to Delaware prior to closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212407,"accession_number":"0001493152-24-028770","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-07-23T23:59:59+00:00","items":["1.02","9.01"],"status":"ready","headline":"PowerUp Acquisition terminates merger with Visiox Pharmaceuticals on July 19","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated Merger Agreement with Visiox Pharmaceuticals due to failure to satisfy closing conditions by June 30, 2024.","Company intends to continue evaluating other business combination targets but provides no assurance.","Termination effective July 19, 2024; no transaction resulted.","No financial terms of the abandoned merger were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231366,"accession_number":"0001493152-24-023111","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition amends merger with Visiox: Outside Date extended to June 30, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Outside Date moved from May 31 to June 30, 2024; PowerUp's indebtedness cap increased to $2M.","Net tangible asset test eliminated; minimum cash condition reduced from $5M to $1.00.","Visiox must use best efforts to complete labeling/compliance for inventory by June 30, 2024.","Visiox must raise at least $500K capital by June 30; $350K allocated to labeling project.","From May 30 to closing, Visiox cannot make expenditures over $1K without PowerUp's approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231365,"accession_number":"0001493152-24-021628","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. shareholders approve extension of business combination deadline to Feb 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved extending the deadline to consummate an initial business combination from May 23, 2024 to February 17, 2025.","Shareholders also approved removing the requirement that the company have at least $5,000,001 in net tangible assets before closing a deal.","A total of 1,226,085 Class A ordinary shares were redeemed for cash in connection with the meeting.","Both proposals passed with overwhelming support: Extension 7,753,807 for / 62,254 against; NTA removal 7,816,061 for / 0 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231364,"accession_number":"0001493152-24-020970","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp enters non-redemption pact; up to 450K shares held, sponsor to transfer shares to preserve trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-redemption agreement with unaffiliated shareholder for up to 450,000 Public Shares at the May 22, 2024 extraordinary general meeting to approve extension.","Sponsor will transfer 25,000 Founder Shares and 25,000 New Issued Shares (to be issued at business combination close) for each 150,000 non-redeemed shares.","Agreement aims to increase funds remaining in trust account; extension would push business combination deadline to February 17, 2025.","Transfer of shares conditioned on approval of extension at meeting and consummation of initial business combination.","Investor waives redemption rights on the specified shares and agrees not to redeem them in connection with the extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231363,"accession_number":"0001493152-24-020792","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"PowerUp Acquisition postpones extension vote to May 22; enters non-redemption agreements to limit trust redemptions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extraordinary general meeting further postponed to 2:00 p.m. ET on May 22, 2024 to vote on extending business combination deadline to Feb. 17, 2025.","Shareholders may submit or withdraw redemption requests by 5:00 p.m. ET on May 20, 2024 (same day as filing).","Sponsor SRIRAMA Associates enters non-redemption agreements; for every 150,000 non-redeemed shares, sponsor transfers 50,000 Class A shares to agreeing shareholders.","Non-redemption agreements aim to increase funds remaining in trust account after the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231362,"accession_number":"0001493152-24-020292","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2024-05-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PowerUp Acquisition postpones extraordinary general meeting to May 21; shareholders to vote on extension to Feb 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Meeting postponed from May 17 to May 21, 2024 at 9:00 a.m. ET.","Shareholders will vote on extending business combination deadline from May 23, 2024 to February 17, 2025.","Redemption deadline extended to May 17, 2024; shareholders can withdraw previously submitted requests.","No changes to record date, location, or proposals to be voted on."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":267221,"accession_number":"0001493152-23-046395","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-12-28T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. enters merger with Visiox Pharmaceuticals for $80M base consideration","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Base merger consideration of $80M, subject to net working capital, transaction expenses, and indebtedness adjustments.","Earnout: up to 6M additional shares tied to Omlonti first commercial sale within 12 months and stock price targets of $12.50 and $15.00.","Post-closing board: 5 directors (2 from PowerUp, 3 from Visiox); CEO and CFO will be Visiox's executives.","Closing conditions include net tangible assets >= $5,000,001 and at least $5M in trust or PIPE after redemptions; Outside Date May 31, 2024.","Also disclosed $250K loan from SSVK Associates to sponsor, then to PowerUp, repayable in cash or shares at $10/share conversion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284514,"accession_number":"0001493152-23-029981","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-08-23T23:59:59+00:00","items":["1.01","5.02","8.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. changes sponsor, board and officers; new CEO appointed","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New sponsor SRIRAMA Associates acquired 4,317,500 Class A shares and 6,834,333 warrants for $1 total.","All prior directors (Hack, Tretton, Blacklow, Uhrman, Campbell) and officers resigned.","Surendra Ajjarapu appointed CEO and Chairman; Howard Doss appointed CFO.","Trust account true-up payment of ~$0.02/share paid to redeeming shareholders on Aug 18, 2023.","New independent directors: Michael Peterson, Donald Fell, Mayur Doshi, Avinash Wadhwani."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284513,"accession_number":"0001104659-23-090934","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PowerUp Acquisition Corp. corrects redemption price by $0.02, plans true-up payment","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Redemption price for May 18, 2023 public share redemption corrected from $10.55 to $10.57 per share.","True-up payment of approximately $0.02 per share to holders of record as of April 19, 2023 who redeemed.","Company expects payment to be made promptly.","Correction stems from notification by Equiniti Trust Company (f/k/a American Stock Transfer & Trust Company)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":284512,"accession_number":"0001104659-23-082105","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition Corp. enters sponsor transfer agreement with SRIRAMA Associates for $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sponsor sells 4,317,500 Class A shares and 6,834,333 private warrants to SRIRAMA for $1.00, payable at business combination.","SRIRAMA assumes SPAC's public reporting, D&O insurance, outstanding legal fees, and administrative services balance of $182,689.","SRIRAMA will replace current directors and officers with its own selections; existing officers and directors to resign at closing.","Post-transfer Sponsor retains 2,870,000 Class A shares and 2,929,000 private warrants; 750,000 shares subject to non-redemption agreements.","Closing expected on or before August 18, 2023, subject to board approval, member approval, underwriter waiver, and filing of Q2 10-Q."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304197,"accession_number":"0001104659-23-064154","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K/A","filed_at":"2023-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"PowerUp Acquisition amends 8-K to correct redemption price to $284M ($10.55/share)","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Corrects redemption price from $283M ($10.51/share) to $284M ($10.55/share) for public shares tendered at May 2023 EGM.","26,946,271 public shares redeemed; approx $284M removed from trust account, leaving $19M and 1,803,729 shares outstanding.","No other changes to original filing; this is solely a price correction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304202,"accession_number":"0001104659-23-063676","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-05-23T23:59:59+00:00","items":["5.03","5.07","8.01","9.01"],"status":"ready","headline":"PowerUp Acquisition extends deadline to May 2024; ~$283M redeemed from trust","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved extension of business combination deadline from May 23, 2023 to May 23, 2024.","Approximately 26.95M public shares redeemed, removing ~$283M (≈$10.51/share) from trust; ~$20M remains.","Following redemptions, only ~1.8M public shares outstanding (from ~28.75M pre-redemption).","All 7,187,500 Class B shares converted to Class A on a one-for-one basis; no Class B shares remain.","Post-conversion and redemptions, ~8.99M Class A shares outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304201,"accession_number":"0001104659-23-060945","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp enters additional non-redemption deals covering 1.5M shares ahead of extension vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-redemption agreements with unaffiliated third parties on May 9 and May 12, 2023 covering 1,500,000 Class A shares.","In exchange, Sponsor transfers 750,000 Class B shares to those investors after a business combination.","Shares remain in trust after Extraordinary General Meeting; extension proposal seeks to push deadline to May 2024.","Agreements are not expected to affect approval likelihood but will increase trust account funds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304200,"accession_number":"0001104659-23-057817","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"PowerUp Acquisition enters additional Non-Redemption Agreements covering 750,000 shares for extension vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Five additional Non-Redemption Agreements with unaffiliated third parties covering 750,000 Class A ordinary shares.","Sponsor to transfer 375,000 Class B ordinary shares to investors post-business combination if shares held through meeting.","Agreements increase funds remaining in trust after extraordinary general meeting to approve extension to May 23, 2024.","Total non-redeemed shares now 900,000 (previous 150,000 + 750,000) under all Non-Redemption Agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":304199,"accession_number":"0001104659-23-056027","cik":1847345,"company_name":"Aspire Biopharma Holdings, Inc.","ticker":"ASBP","form_type":"8-K","filed_at":"2023-05-04T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"PowerUp Acquisition trust balance stands at $303.3M ($10.55/share) as of May 3, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trust account held at Citibank with American Stock Transfer as trustee; balance $303,324,683.","Per-share trust value of $10.55 for public shares, updated ahead of extension vote.","Company filed Definitive Proxy Statement on April 21, 2023 for Extension Amendment Proposal.","Proceeds from IPO remain in trust pending potential business combination or extension."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6048742.429980276,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-05-04T23:59:59+00:00|304199"}